

Neurizon Raises \$5m via Institutional Placement

Not for release to US wire services or distribution in the United States

Highlights:

- Firm commitments secured to raise \$5m through the issue of new fully paid ordinary shares at \$0.12 per share
- In addition, the Board and management will subscribe for \$0.2m under the Placement, \$130,000 of which is subject to shareholder approval
- The Placement was strongly supported by both new and existing institutional investors
- Strengthened balance sheet supports preparation for entry into the HEALEY ALS Platform Trial in Q4 CY25, pending FDA clearance of Company's IND
- Placement proceeds will also be used to advance pre-clinical programs, GMP manufacturing, regulatory filings and working capital

18 September 2025 – Melbourne Australia: Neurizon® Therapeutics Limited (ASX: NUZ & NUZOA) ("Neurizon" or "the Company"), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to advise it has secured firm commitments from new and existing institutional and professional investors to raise \$5m (before costs) at an issue price of \$0.12 per Share (the "Placement"). In addition, the Board and management team will subscribe for \$0.2m under the Placement, \$130,000 which is subject to shareholder approval at the annual general meeting of the Company to be held on or around 26 November 2025.

The Placement follows a series of recent clinical, regulatory, and operational milestones that have strengthened Neurizon's strategic position, including positive topline Phase 1 Open Label Extension study results and execution of the global licensing agreement with Elanco¹.

Funds will be used to support preparations for Neurizon's planned entry in the HEALEY ALS Platform Trial in Q4 CY2025, pending FDA clearance of its IND, along with manufacturing of second and third GMP registration batches, regulatory filings, and pre-clinical initiatives designed to expand the potential of NUZ-001 across other neurodegenerative diseases. Funds will also provide general working capital.

Non-executive Chairman, Mr Sergio Duchini commented: "We are delighted by the strong support from both new and existing institutional investors. Importantly, this raise positions Neurizon to advance the development of NUZ-001 in ALS and expand its potential across related neurodegenerative diseases.

This Placement strengthens our balance sheet as we prepare for the pivotal Phase 2/3 HEALEY ALS Platform Trial and allows us to continue expanding the potential of NUZ-001 through our pre-clinical program. We are grateful for the ongoing support of our existing shareholders and welcome new institutional investors."

Placement details:

Neurizon has received firm commitments to raise \$5m from institutional and sophisticated investors. In addition, the Board and management have agreed to subscribe for \$0.2m under the Placement, \$130,000 of which is subject to shareholder approval at the annual general meeting of the Company (to be held on or around 26 November 2025).

A total of 43,333,334 shares is intended to be issued under the Placement, 42,249,999 under the Company's ASX Listing Rule 7.1A placement capacity and 1,083,335 shares to Directors, to be issued subject to shareholder approval at the annual general meeting of the Company to be held on or around 26 November 2025.

¹ In respect of Elanco, the Company is currently progressing with Elanco the possibility of the Company agreeing to appoint a nominee of Elanco as an observer to the Board of the Company. There is no assurance that those discussions will result in the appointment by the Company of any such observer.

The Placement price of \$0.12 represents a 14.3% discount to the last trading price of \$0.14 on 15 September 2025 and a 18.9% discount to the 5-trading day volume weighted average price (VWAP) of \$0.148.

Placement Shares will be listed on the ASX and rank pari-passu with the existing fully paid ordinary shares. The Placement is expected to settle on 23 September 2025, with Shares allotted on or around 24 September 2025. Director participation is expected to settle shortly following shareholder approval at the Annual General Meeting of the Company to be held on or around 26 November 2025.

Petra Capital Pty Limited acted as sole lead manager and sole bookrunner to the Placement.

-ENDS-

This announcement has been authorized for release by the Board of Neurizon Therapeutics Limited.

All amounts are in Australian dollars unless otherwise indicated.

For further information, please contact:

Neurizon Therapeutics
Dr Michael Thurn
CEO & Managing Director
enquiries@neurizon.com
+61 (3) 9692 7222

Neurizon Therapeutics
Lidija Damjanovic
Marketing & Corporate Affairs
lidija@neurizon.com
+61 (0) 425 700 504

Investor Relations
Henry Jordan
Six Degrees Investor Relations
henry.jordan@sdir.com.au
+61 (0) 431 271 538

Not an offer of securities

This announcement has been prepared for publication in Australia and may not be released to US wire services or distributed in the United States. This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction. Any securities described in this announcement have not been, and will not be, registered under the US Securities Act of 1933 and may not be offered or sold in the United States except in transactions exempt from, or not subject to, the registration requirements of the US Securities Act and applicable US state securities laws.

About Neurizon Therapeutics Limited

Neurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment of ALS, which is the most common form of motor neurone disease. Neurizon's strategy is to accelerate access to effective ALS treatments for patients while exploring the potential of NUZ-001 for broader neurodegenerative applications. Through international collaborations and rigorous clinical programs, Neurizon is dedicated to creating new horizons for patients and families impacted by complex neural disorders. NUZ-001 is an investigational product and is not approved for commercial use in any jurisdiction.

Neurizon Investor Hub

We encourage you to utilise our Investor Hub for any enquiries regarding this announcement or other aspects concerning Neurizon. This platform offers an opportunity to submit questions, share comments, and view video summaries of key announcements.

To access Neurizon Investor Hub please scan the QR code or visit
<https://investorhub.neurizon.com>

